We Share a Mutual Goal:
to Make Drugs That Work
Partner with the leaders in predictive transcriptomics to accelerate your drug discovery and development programs.
Your Data, Our AI and Expertise
How We Engage
You have clinical and multi-omic data capable of unlocking key insights in drug discovery and development.
Our mission is to help you drive clinical and scientific decision-making forward by applying advanced computational methods that reveal the answers lying within your data.
Our joint development teams consider your scientific questions, generate hypotheses, and prioritize opportunities likely to yield the most value
The most advanced available, proprietary computational methods are employed to analyze, visualize, and document results
Source & Prep Data
We combine your data (patient data, meta data, and RNA-seq) with publicly available data (public samples, literature) for analysis and reanalysis
We interpret your results to generate insights/action including preparing evidence for publication and regulatory submissions
Past Projects Include
- Organoid & cell lines: baselining analysis & multi-omic analysis (post-treated)
- Tumor: multiple dose combinations; factorial, time course & alternate dosing analysis
- Cross-model analysis of multi-omic biomarkers predictive of response & resistance
- Review of biomarker incidence in samples with relevant cancers in public data
- Patient stratification and response prediction
- Characterize the transcriptomic impact and functional profiling to uncover biological effects
- Explore biomarkers of response and resistance in each arm and cross arms
- Explore potential targets in resistance
- Assist in preparing evidence and analysis for publication and regulatory purposes
Accelerating Knowledge to Benefit Patients
Identifying Novel Gene Targets in ICI-resistant Gastric Cancer
Discovering Responder Predictive Markers in mCRC
Validating a Drug Candidate by Determining Gene-Expression Impact
Ocean Genomics assisted a partner in identifying 22 significant pathways from a list of 4700 differentially expressed genes in response to a promising melanoma candidate.
Furthermore, we demonstrated that the ratio of beneficial to non-beneficial pathway impacts was higher than standard of care, enabling candidate to advance.
Co-Developing Assets with a Strategic Partner Across Leading Cancer Centers
Ocean Genomics’ partnership with Geninus to develop bio-predictive assets leveraged their data sets to develop and commercialize a predictive biomarker for response to immunotherapy in gastric cancer.